Comparative Effectiveness and Safety of Sodium-Glucose Cotransporter 2 Inhibitors Versus Glucagon-Like Peptide 1 Receptor Agonists in Older Adults.
Elisabetta PatornoElisabetta PatornoLily G BessetteDae H KimChintan DaveChintan V DaveMedha N MunshiSebastian SchneeweissDeborah J WexlerSeoyoung C KimPublished in: Diabetes care (2021)
Among older adults, those taking SGLT2i had similar MACE risk, decreased HHF risk, and increased risk of DKA, LLA, and genital infections versus those taking GLP-1RA.